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BACKGROUND
In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs 
and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety 
of secukinumab, an anti–interleukin-17A monoclonal antibody, in such patients.
METHODS
In this double-blind, phase 3 study, 606 patients with psoriatic arthritis were ran-
domly assigned in a 1:1:1 ratio to receive intravenous secukinumab (at a dose of 
10 mg per kilogram) at weeks 0, 2, and 4, followed by subcutaneous secukinumab 
at a dose of either 150 mg or 75 mg every 4 weeks, or placebo. Patients in the 
placebo group were switched to subcutaneous secukinumab at a dose of 150 mg 
or 75 mg at week 16 or 24, depending on clinical response. The primary end point 
was the proportion of patients with an American College of Rheumatology 20 
(ACR20) response at week 24, defined as a 20% improvement from baseline in the 
number of tender and swollen joints and at least three other important domains.
RESULTS
ACR20 response rates at week 24 were significantly higher in the group receiving 
secukinumab at doses of 150 mg (50.0%) and 75 mg (50.5%) than in those receiv-
ing placebo (17.3%) (P<0.001 for both comparisons with placebo). Secondary end 
points, including the ACR50 response and joint structural damage, were signifi-
cantly better in the secukinumab groups than in the placebo group. Improvements 
were sustained through 52 weeks. Infections, including candida, were more com-
mon in the secukinumab groups. Throughout the study (mean secukinumab ex-
posure, 438.5 days; mean placebo exposure, 128.5 days), four patients in the 
secukinumab groups had a stroke (0.6 per 100 patient-years; 95% confidence in-
terval [CI], 0.2 to 1.5), and two had a myocardial infarction (0.3 per 100 patient-
years; 95% CI, 0.0 to 1.0), as compared with no patients in the placebo group.
CONCLUSIONS
Secukinumab was more effective than placebo in patients with psoriatic arthritis, 
which validates interleukin-17A as a therapeutic target. Infections were more com-
mon in the secukinumab groups than in the placebo group. The study was neither 
large enough nor long enough to evaluate uncommon serious adverse events or the 
risks associated with long-term use. (Funded by Novartis Pharma; ClinicalTrials.gov 
number, NCT01392326.)
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Psoriatic arthritis is a chronic, sys-temic inflammatory disease that affects peripheral joints, connective tissues, and 
the axial skeleton and is associated with psoria-
sis of the skin and nails.1,2 Inhibitors of tumor 
necrosis factor (TNF) have significantly improved 
outcomes among patients with psoriatic arthri-
tis.3-6 However, some patients who have received 
these agents have not had adequate benefit, have 
not had a durable response, or have had adverse 
events.1,2 Effective therapies with a different 
mechanism of action are needed.
Interleukin-17A is postulated to play a role in 
the pathogenesis of psoriatic arthritis. Increased 
levels of cells that produce interleukin-17A are 
found in the circulation, joints, and skin plaques 
of patients with psoriatic arthritis,7-10 and these 
levels have been shown to correlate with mea-
sures of disease activity and structural damage.11 
A phase 2 study showed that the inhibition of 
the interleukin-17A receptor improved signs and 
symptoms of psoriatic arthritis.12 Secukinumab, 
a high-affinity, human immunoglobulin G1 mono-
clonal antibody that selectively binds to and 
neutralizes interleukin-17A, has shown efficacy 
in a number of immune-mediated inflammatory 
diseases, including psoriasis and ankylosing 
spondylitis.13,14
FUTURE 1 is an ongoing, 2-year, phase 3 study 
assessing the effect of secukinumab on signs 
and symptoms, joint structural damage, physical 
function, and quality of life among patients with 
psoriatic arthritis. Here, we report efficacy data 
through week 24 (primary end point) and week 
52 (interim follow-up analysis). Safety data are 
reported up to the interim follow-up analysis.
Me thods
Study Population
Study patients were 18 years of age or older, 
fulfilled the Classification Criteria for Psoriatic 
Arthritis (CASPAR),15 and had active disease, 
which was defined as three or more tender joints 
and three or more swollen joints, despite previous 
treatment with nonsteroidal antiinflammatory 
drugs, disease-modifying antirheumatic drugs, 
or TNF inhibitors. The concomitant use of oral 
glucocorticoids (at a dose of ≤10 mg per day of 
prednisone or its equivalent) and methotrexate 
(at a dose of ≤25 mg per week) was permitted, 
provided that the dose was stable. Patients who 
had previously received anti-TNF therapy were 
required either to have had an inadequate re-
sponse or to have stopped treatment because of 
side effects. For patients who had received anti-
TNF agents, a washout period of 4 to 10 weeks 
before randomization was required.
Key exclusion criteria included previous ther-
apy with biologic drugs other than anti-TNF 
agents, treatment with more than three anti-TNF 
therapies, the presence of active inflammatory 
diseases other than psoriatic arthritis, and active 
infection in the 2 weeks before randomization 
or a history of ongoing, chronic, or recurrent 
infections. Additional information is provided in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org.
Study Oversight
The study was approved by the institutional re-
view board or ethics committee at each participat-
ing site and was conducted in accordance with 
the principles of the Declaration of Helsinki. All 
patients provided written informed consent.
The study was sponsored by Novartis Pharma 
and designed by the scientific steering commit-
tee and Novartis personnel. Data were collected 
according to Good Clinical Practice guidelines 
by the study investigators and were analyzed by 
the sponsor. Statistical analyses were performed 
by statisticians employed by the sponsor and were 
reviewed by all the authors. Agreements between 
the sponsor and the investigators included provi-
sions relating to confidentiality of the study 
data. The first draft of the manuscript was writ-
ten by a medical writer funded by the sponsor. 
All the authors vouch for the accuracy and com-
pleteness of the data and analyses and for the 
fidelity of this report to the study protocol, 
which is available at NEJM.org.
Study Design
From September 29, 2011, to October 1, 2012, 
we conducted this multicenter, randomized, 
double-blind, placebo-controlled trial at 104 sites 
in North America and South America, Europe, 
the Middle East, Australia, and Asia. After a 
4-week screening period, eligible patients were 
randomly assigned in a 1:1:1 ratio by means of 
an interactive voice–Web response system to one 
of two secukinumab dose groups or a placebo 
group. Patients in the secukinumab groups re-
ceived an intravenous dose of 10 mg per kilogram 
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of body weight at baseline and weeks 2 and 4, 
followed by subcutaneous secukinumab at a dose 
of either 150 mg or 75 mg every 4 weeks there-
after. Patients in the placebo group were treated 
according to the same intravenous-to-subcutane-
ous administration schedule.
At week 16, investigators who were unaware 
of study-group assignments classified all the 
patients as having had a response (which was 
defined as an improvement of 20% or more from 
baseline in the number of tender and swollen 
joints) or no response. Placebo-treated patients 
underwent randomization for a second time in a 
1:1 ratio to receive subcutaneous secukinumab at 
a dose of either 150 mg or 75 mg every 4 weeks, 
starting at week 16 (for patients who were clas-
sified as having had no response) or week 24 (for 
those who were classified as having had a re-
sponse). In the efficacy analyses, the placebo-
controlled period included data through week 
24, with imputation for patients who switched to 
active treatment at week 16. In the safety analy-
ses, the placebo-controlled period included data 
only through week 16, when patients received 
the originally assigned study medication.
The randomization of patients was stratified 
according to previous anti-TNF therapy. Approxi-
mately 70% of the patients were required to have 
received no previous anti-TNF therapy.
Assessments
The primary objective was to assess the propor-
tion of patients meeting the criteria for 20% 
improvement according to the criteria of the 
American College of Rheumatology (ACR20 re-
sponse)16 at week 24. The ACR20 response was 
defined as an improvement of 20% or more from 
baseline in the number of tender joints (from an 
analysis of 78 joints), in the number of swollen 
joints (from an analysis of 76 joints), and in three 
of the following five domains: a patient’s global 
assessment of disease, a physician’s global as-
sessment of disease, and a patient’s assessment 
of pain (with all three evaluations measured on 
a visual-analogue scale of 0 to 100); disability (as 
measured by the score on the Health Assessment 
Questionnaire–Disability Index [HAQ-DI], which 
ranges from 0 to 3, with higher scores indicat-
ing greater disability); and the level of acute-
phase reactants (as measured by the level of high-
sensitivity C-reactive protein or the erythrocyte 
sedimentation rate).
Secondary objectives included assessment of 
the following categories at week 24: the propor-
tion of patients with improvement of at least 
75% and 90% in the score on the psoriasis area-
and-severity index (PASI 75 and PASI 90, respec-
tively)17 among patients with at least 3% of body-
surface area that was affected by psoriasis at 
baseline; a change from baseline in the 28-joint 
Disease Activity Score on the basis of levels of 
C-reactive protein (DAS28-CRP), with scores 
ranging from 2 to 10, and a score of more than 
5.1 indicating active disease, a score of up to 3.2 
indicating low disease activity, and a score of 
less than 2.6 indicating remission)18; quality of 
life, as assessed with the use of the physical 
component summary score of the Medical Out-
comes Study 36-Item Short-Form Health Survey 
(SF-36), version 2, with scores ranging from 0 to 
100, and 0 indicating maximum disability and 
100 indicating no disability, and a minimum 
clinically important difference of at least 2.5 
points used for the analysis19; physical function, 
as assessed with the use of the HAQ-DI20; the 
proportion of patients with improvement of at 
least 50% according to the criteria of the ACR 
(ACR50 response); and radiographic progres-
sion. In addition, among patients who had either 
dactylitis or enthesitis at baseline, the presence 
of dactylitis was assessed by means of a dacty-
litic digit count, with a score of 1 for the pres-
ence of dactylitis and 0 for the absence in each 
digit, for an overall score ranging from 0 to 20; 
the presence of enthesitis was assessed by means 
of a 4-point enthesitis index to measure the 
presence (score of 1) or absence (score of 0) of 
tenderness at the lateral epicondyle humerus (left 
and right) and proximal achilles (left and right).
Radiographic progression was assessed with 
the use of the van der Heijde–modified total 
Sharp score (mTSS), which ranges from 0 to 528, 
with higher scores indicating greater erosion or 
narrowing of joint spaces.21 Radiography of the 
hands, wrists, and feet was performed at base-
line, at week 16 or 24 (depending on response), 
and at week 52. Two independent readers scored 
all images centrally. Exploratory objectives in-
cluded assessment of the proportion of patients 
with improvement of at least 70% according to 
the criteria of the ACR (ACR70 response). Pre-
specified subgroup analyses on the basis of previ-
ous anti-TNF therapy were performed for key 
efficacy end points. Efficacy assessments were 
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conducted at baseline and throughout the study, 
with key assessments at week 24 (primary end 
point) and week 52 (interim follow-up analysis).
Safety was evaluated by means of open as-
sessment of adverse events, serious adverse events, 
and routine laboratory values. The National Can-
cer Institute Common Terminology Criteria for 
Adverse Events, version 4.0,22 was used to grade 
the severity of adverse events. Potential major 
adverse cardiac events were adjudicated by an 
independent expert committee. Blood samples 
were obtained at baseline and weeks 24 and 52 
for assessment of secukinumab immunogenicity 
with the use of a homogeneous Meso Scale Dis-
covery bridging assay.23
Statistical Analysis
We calculated that the enrollment of 600 pa-
tients (200 in each study group) would provide a 
power of more than 90% to detect a treatment 
difference between a secukinumab regimen and 
placebo with respect to the primary end point, 
assuming response rates for placebo and secu-
kinumab of 22% and 49%, respectively, at a two-
sided significance level of 0.025. Primary and 
secondary efficacy analyses included all patients 
according to the treatment assigned at random-
ization. Statistical analyses at week 24 used the 
imputation of missing values as a nonresponse 
for binary variables, a mixed-effects repeated-
measures model for continuous variables, and 
linear extrapolation for radiographic data. Analy-
ses followed a predefined hierarchical hypothe-
sis-testing strategy to adjust for multiplicity to 
maintain a familywise type I error of 5%. Ac-
cording to this strategy, the statistical signifi-
cance of each secondary end point could be in-
vestigated only if the previous end point was 
significant (P<0.025 for end points tested at in-
dividual doses; P<0.05 for pooled analyses). The 
statistical-hierarchy testing order was as follows: 
ACR20 response, PASI 75, PASI 90, DAS28-CRP, 
physical component summary of SF-36, HAQ-DI, 
ACR50, mTSS (for pooled secukinumab doses), 
dactylitis and enthesitis (for pooled secukinumab 
doses), and mTSS (for individual doses). Patients 
in the placebo group who were switched to ac-
tive treatment at week 16 were imputed to have 
had no response in the analysis at week 24. To 
avoid bias, secukinumab-treated patients who 
had no response at week 16 were also imputed 
to have had no response at week 24.
For binary variables, P values are from a logis-
tic-regression model with treatment and previous 
use of anti-TNF therapy as factors, with body 
weight at baseline as a covariate. The baseline 
score was a covariate in the analysis of some end 
points. For continuous variables, P values are 
from a repeated-measures mixed model, with 
treatment regimen, analysis visit, and previous 
use of anti-TNF therapy as factors and with body 
weight and baseline score as continuous covari-
ates. Treatment according to analysis visit and 
baseline score according to analysis visit were 
used as interaction terms, and an unstructured 
covariance structure was assumed.
Both inferential analyses (with imputation) 
and descriptive summaries (on observed data) 
were performed on data from week 28 to week 
52. In the inferential analysis of binary variables 
during this period, patients who withdrew from 
the study were considered to have had no re-
sponse from the time of withdrawal. In contrast 
to the method that was used in the primary 
analysis, in the analyses from week 20 through 
week 52, no imputation was applied as a result 
of the clinical response of a patient at week 16. 
Patients for whom responses could not be calcu-
lated at a specific time point were classified as 
having had no response. Analyses of clinical 
responses to secukinumab from week 28 to 
week 52 include only patients who underwent 
the first randomization to active treatment.
Safety analyses included all patients who un-
derwent randomization and who received at 
least one dose of a study drug. Additional infor-
mation regarding the statistical analysis is pro-
vided in the Supplementary Appendix. All re-
ported P values are two-sided.
R esult s
Patients
Of the 606 patients who underwent randomiza-
tion (202 in each study group), 553 (91.3%) com-
pleted the 24-week evaluation period and 515 
(85.0%) completed the 52-week evaluation period 
(Fig. S1 in the Supplementary Appendix). The 
patients’ demographic and disease characteris-
tics and previous or concomitant use of medica-
tions were similar across the study groups at 
baseline (Table 1). More than half the patients 
(53.6%) had psoriasis affecting at least 3% of 
their body-surface area; 53.5% had dactylitis, 
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and 61.4% had enthesitis. A total of 70.6% of 
the patients had received no previous anti-TNF 
therapy, and 60.7% were receiving concomitant 
methotrexate.
Efficacy
Secukinumab was superior to placebo with re-
spect to all the primary and secondary end 
points that were prespecified in the hierarchi-
cal statistical testing. At week 24, the proportion 
of patients with an ACR20 response was signifi-
cantly higher among patients receiving secukinu-
mab at either the 150-mg dose or the 75-mg 
dose than among those receiving placebo (50.0% 
and 50.5%, respectively, vs. 17.3%) (P<0.001 for 
both comparisons with placebo) (Table 2 and 
Fig. 1). At week 24, the proportion of patients 
with an ACR50 response was significantly high-
er in the secukinumab groups than in the pla-
cebo group (Table 2), as was the proportion of 
patients with an ACR70 response in prespecified 
exploratory analyses (Fig. S2 in the Supplemen-
tary Appendix). Significant improvements with 
secukinumab versus placebo were observed for 
all other secondary end points at week 24 that 
were prespecified in hierarchical statistical test-
ing, including PASI 75 and PASI 90 responses, 
the change from baseline in DAS28-CRP, the 
SF-36 physical component summary, HAQ-DI 
scores, and the proportion of patients who had 
resolution of dactylitis and enthesitis (Table 2). 
Patients in the secukinumab groups also had 
significantly less radiographic progression, as 
measured by the change from baseline on the 
mTSS at week 24, than did patients in the placebo 
group (P<0.05 for both comparisons) (Table 2, 
and Fig. S3 in the Supplementary Appendix).
In prespecified exploratory subgroup analy-
ses, improvements in ACR response rates and 
disease activity at week 24 in the secukinumab 
groups, as compared with the placebo group, 
were observed regardless of previous exposure 
to anti-TNF agents (Table S1 in the Supplemen-
tary Appendix). At week 24, among patients who 
had received no previous anti-TNF therapy, an 
ACR20 response was reported in 78 of 143 pa-
tients (54.5%) who received 150 mg of secukinu-
mab and in 79 of 142 patients (55.6%) who re-
ceived 75 mg of secukinumab, as compared with 
25 of 143 patients (17.5%) in the placebo group. 
At the same time, among patients who had a 
previous inadequate response to anti-TNF therapy 
or who had unacceptable side effects, an ACR20 
response was reported in 23 of 59 patients 
(39.0%) who received 150 mg of secukinumab, 
23 of 60 patients (38.3%) who received 75 mg of 
secukinumab, and 10 of 59 patients (16.9%) in 
the placebo group. In a post hoc analysis, ACR20 
response rates were better in the secukinumab 
groups than in the placebo group at week 24, 
regardless of concomitant methotrexate use 
(Fig. S4 in the Supplementary Appendix).
Clinical benefits in the secukinumab groups 
were sustained through 52 weeks of therapy 
(Table S2 in the Supplementary Appendix). On 
the basis of a conservative estimate of efficacy 
with missing values imputed as no response, at 
week 52 in the secukinumab groups, an ACR20 
response was reported in 121 of 202 patients 
(59.9%) among those receiving 150 mg and in 
115 of 202 patients (56.9%) among those receiv-
ing 75 mg (Fig. 1). On the basis of observed 
data, the corresponding numbers for the ACR20 
response were 121 of 174 patients (69.5%) and 
115 of 172 patients (66.9%), respectively (Table 
S2 and Fig. S5 in the Supplementary Appendix). 
ACR50 and ACR70 results are presented in Table 
S2 and Figures S2 and S5 in the Supplementary 
Appendix. Patients in the placebo group had im-
provements in ACR20 response rates after switch-
ing to secukinumab (Fig. S6 in the Supplemen-
tary Appendix).
Safety
During the 16-week placebo-controlled period, 
adverse events were reported in 64.9% of pa-
tients receiving 150 mg of secukinumab, in 
60.4% of those receiving 75 mg of secukinumab, 
and in 58.4% of those receiving placebo. Rates 
of nonfatal serious adverse events and discon-
tinuations were similar across the study groups 
(Table 3). Nasopharyngitis, headache, and upper 
respiratory tract infection were the most com-
mon adverse events and were more frequent 
among patients in the secukinumab groups than 
among those in the placebo group. During the 
placebo-controlled period, infections were more 
common among patients in the secukinumab 
groups.
Across the entire safety-data reporting period, 
the maximum exposure to secukinumab was 
103 weeks, with a mean exposure of 438.5 days 
and a median exposure of 456 days. During this 
period, the exposure-adjusted rates of serious 
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Characteristic
Secukinumab, 150 mg 
 (N = 202)
Secukinumab, 75 mg 
(N = 202)
Placebo  
(N = 202)
Age — yr 49.6±11.8 48.8±12.2 48.5±11.2
Female sex — no. (%) 106 (52.5) 118 (58.4) 106 (52.5)
Weight — kg 84.2±21.1 84.5±19.6 80.0±20.5
Race — no. (%)†
White 162 (80.2) 165 (81.7) 154 (76.2)
Black 3 (1.5) 2 (1.0) 0
Asian 36 (17.8) 33 (16.3) 46 (22.8)
Other 1 (0.5) 1 (0.5) 2 (1.0)
No. of previous anti-TNF drugs — no. (%)
0 143 (70.8) 142 (70.3) 143 (70.8)
1 39 (19.3) 35 (17.3) 35 (17.3)‡
≥2 20 (9.9) 25 (12.4) 24 (11.9)
Use of methotrexate at randomization — 
no. (%)
121 (59.9) 122 (60.4) 125 (61.9)
Use of systemic glucocorticoid at random-
ization — no. (%)
34 (16.8) 34 (16.8) 27 (13.4)
Patients with specific disease characteris-
tics — no. (%)
Psoriasis affecting ≥3% of body-surface 
area
108 (53.5) 108 (53.5) 109 (54.0)
Dactylitis 104 (51.5) 104 (51.5) 116 (57.4)
Enthesitis 126 (62.4) 129 (63.9) 117 (57.9)
Disease and quality-of-life scores
Tender-joint count (of 78 joints) 23.8±16.4 23.4±17.2 25.1±18.4
Swollen-joint count (of 76 joints) 12.5±9.4 12.7±11.1 14.9±13.1
DAS28-CRP§ 4.8±1.1 4.9±1.2 4.9±1.1
PASI¶ 15.6±13.9 10.7±8.8 15.1±11.6
Physician’s global assessment of dis-
ease activity‖
58.3±18.9 54.3±18.0 56.7±18.8
Modified total Sharp score** 21.9±47.5 20.0±38.8 28.1±62.8
HAQ-DI score†† 1.2±0.7 1.3±0.7 1.2±0.6
Psoriatic arthritis pain‖ 55.7±24.2 55.1±22.1 56.7±21.1
Patient’s global assessment of 
disease activity‖
55.2±24.0 56.1±22.6 55.6±21.7
SF-36 physical component summary‡‡ 36.2±8.1 36.9±8.1 36.8±8.0
*  Plus–minus values are means ±SD. There were no significant differences among the three groups except for the pso-
riasis area-and-severity index (PASI) score (P = 0.003) and weight (P = 0.048). TNF denotes tumor necrosis factor.
†  Race was self-reported. Race was not reported for one patient in the group receiving 75 mg of secukinumab.
‡  One patient in this group received one dose of infliximab, which was subsequently discontinued for logistic reasons 
rather than because of an inadequate response. The patient was reported as having received no previous anti-TNF 
therapy.
§  The 28-joint Disease Activity Score (DAS28), which is based on the level of C-reactive protein (CRP), ranges from 2 to 
10, with higher scores indicating more severe disease activity (with >5.1 indicating active disease, ≤3.2 indicating low 
disease activity, and <2.6 remission).
¶  PASI scores range from 0 to 72, with higher scores indicating more severe disease. PASI was assessed only in pa-
tients in whom psoriasis affected at least 3% of the body-surface area at baseline.
‖  This evaluation is based on a visual-analogue scale of 0 to 100, with higher scores indicating greater disease activity 
or pain.
**  The van der Heijde–modified total Sharp score ranges from 0 to 528, with higher scores indicating more articular 
damage.
††  Scores on the Health Assessment Questionnaire–Disability Index (HAQ-DI) range from 0 to 3, with higher scores in-
dicating greater disability.
‡‡  Scores on the physical component summary of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-
36) range from 0 to 100, with 0 representing maximum disability and 100 no disability; scores lower than 50 reflect 
less-than-average health, and scores greater than 50 reflect better-than-average health.
Table 1. Demographic and Disease Characteristics of the Patients at Baseline.*
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adverse events among patients receiving secu-
kinumab were 11.5 and 7.4 per 100 patient-years 
among those receiving 150 mg and 75 mg, re-
spectively (Table 3). Serious adverse events are 
listed in Table S3 in the Supplementary Appen-
dix. Through 16 weeks, one patient receiving 
75 mg of secukinumab had a stroke. After week 
16, an additional three patients had a stroke, 
totaling four patients for the entire safety re-
porting period; all these patients were receiving 
75 mg of secukinumab (exposure-adjusted rate, 
0.6 per 100 patient-years; 95% confidence inter-
val [CI], 0.2 to 1.5). In addition, two patients 
(one in each secukinumab group) had a myocar-
dial infarction (rate, 0.3 per 100 patient-years; 
95% CI, 0.0 to 1.0). Of these six patients, four 
continued to participate in the study. Additional 
details regarding these patients are provided in 
Table S4 in the Supplementary Appendix. No 
strokes or myocardial infarctions were observed 
in the placebo group (rate, 0 per 100 patient-
years; 95% CI, 0.0 to 5.2). The maximum expo-
sure to placebo was 33 weeks (mean exposure, 
128.5 days; median exposure, 112 days).
Overall, adverse events leading to discontinu-
ations of a study drug were noted in less than 
5% of the patients and were similar among the 
three groups. Oral candidiasis was reported in 
4 patients each in the secukinumab 150-mg and 
75-mg groups; in the 150-mg group, there were 
reports of esophageal candidiasis in 1 patient 
and a candida infection of the skin in another. 
All cases of candidiasis, including one serious 
case, responded to oral therapy, and patients 
continued in the study. No other serious oppor-
tunistic infections or cases of active tuberculosis 
Outcome
Secukinumab, 150 mg 
 (N = 202)
Secukinumab, 75 mg 
 (N = 202)
Placebo 
 (N = 202)
ACR20 response: primary end point — no. (%)† 101 (50.0)‡ 102 (50.5)‡ 35 (17.3)
Prespecified secondary end points
PASI 75 response — no./total no. (%)§ 66/108 (61.1)‡ 70/108 (64.8)‡ 9/109 (8.3)
PASI 90 response — no./total no. (%)§ 49/108 (45.4)‡ 53/108 (49.1)‡ 4/109 (3.7)
Change from baseline in DAS28-CRP −1.62±0.08‡ −1.67±0.09‡ −0.77±0.12
Change from baseline in SF-36 physical com-
ponent summary
5.91±0.53‡ 5.41±0.52‡ 1.82±0.72
Change from baseline in disability assessment 
(HAQ-DI score)
−0.40±0.04‡ −0.41±0.04‡ −0.17±0.05
ACR50 response — no. (%) 70 (34.7)‡ 62 (30.7)‡ 15 (7.4)
Change from baseline in joint structural 
damage (mTSS score)¶
0.13±0.09‖ 0.02±0.12‖ 0.57±0.19
Patients with resolution of dactylitis — no./
total no. (%)**
109/208 (52.4)‖ 18/116 (15.5)
Patients with resolution of enthesitis — no./
total no. (%)**
121/255 (47.5)‖ 15/117 (12.8)
*  Plus–minus values are means ±SE. The change from baseline in the DAS28-CRP and the SF-36 physical component 
summary were calculated as least-squares means in inferential analysis. Prespecified primary and secondary end points 
were analyzed according to a statistical hierarchy. End points are shown in the order of testing, except the effect of 
 individual doses of secukinumab on joint structural damage, which was tested after dactylitis and enthesitis end points.
†  The primary end point was an improvement of at least 20% in the American College of Rheumatology response criteria 
(ACR20 response).
‡  P<0.001 for the comparison with placebo.
§  PASI 75 and PASI 90 denote improvements of 75% and 90%, respectively, in the score on the psoriasis area-and-severity 
index.
¶  Joint structural damage was measured by means of the van der Heijde–modified total Sharp score (mTSS). Data are 
shown for 185 patients who received 150 mg of secukinumab, 181 patients who received 75 mg of secukinumab, and 
179 patients who received placebo. For the pooled secukinumab groups, the mean change from baseline in the mTSS 
score was 0.08±0.07 (P = 0.01).
‖  P<0.05 for the comparison with placebo.
**  For this analysis, data for the two secukinumab groups were pooled.
Table 2. Comparison of Efficacy at Week 24 during the Placebo-Controlled Phase.*
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(new or reactivation of latent infection) were re-
ported. Malignant or unspecified tumors were 
reported in 1 of 295 patients (0.3%) receiving 
150 mg of secukinumab, 3 of 292 patients 
(1.0%) receiving 75 mg of secukinumab, and 
1 of 202 patients (0.5%) receiving placebo. Three 
of 10 patients with anti-secukinumab antibodies 
at baseline showed anti-secukinumab antibodies 
and neutralizing antibodies in all or most post-
baseline samples. Treatment-emergent anti-
secukinumab antibodies were detected in 1 of 
587 patients (0.2%) receiving secukinumab.
Discussion
In this phase 3 study, we found that selective 
inhibition of interleukin-17A with secukinumab 
was significantly better than placebo in improv-
ing the signs and symptoms of psoriatic arthri-
tis, along with patient-reported physical func-
tioning and quality of life, with responses 
sustained during 52 weeks of therapy. In addi-
tion, there was a small reduction in the progres-
sion of measures of structural joint damage 
among patients receiving secukinumab. Pre-
clinical data implicate the interleukin-17 path-
way in the irreversible structural damage ob-
served in inflammatory arthritis.11,24-26 Our data 
provide further evidence that interleukin-17A 
may be a mediator of this process.
It is noteworthy that there was no apparent 
dose–response relationship between the two 
secukinumab groups with respect to efficacy as-
sessments up to week 24, although such an 
analysis was not a predefined end point. This 
lack of difference may be at least partly due to 
the same intravenous loading dose that was ad-
ministered to patients in the two secukinumab 
groups. Further evaluation of the dose–response 
relationship in subsequent subcutaneous admin-
istration of secukinumab is needed.
Even though many patients with psoriatic 
arthritis benefit from anti-TNF therapy, unmet 
needs remain, including an unacceptable side-
effect profile in some patients, lack of primary 
efficacy, loss of efficacy, and immunogenicity 
with these agents in some patients.4,27-30 Secu-
kinumab showed efficacy among patients who 
had received previous anti-TNF therapy and those 
who had received no such therapy, although im-
provements were smaller among patients who 
had received previous anti-TNF therapy.
The safety profile of secukinumab was con-
sistent with the findings in previous studies in-
volving patients with psoriatic arthritis and 
moderate-to-severe plaque psoriasis.13,31 Elevated 
cardiovascular risk among patients with psori-
atic arthritis has been reported previously.32-34 In 
our study, two patients who were receiving 
secukinumab had a myocardial infarction and 
four had a stroke (mean exposure to secukinum-
ab across the study, 438.5 days). No myocardial 
infarctions or strokes were observed in the pla-
cebo group during the shorter placebo-controlled 
period (mean exposure, 128.5 days). Consistent 
with observations from phase 3 studies involv-
ing patients with psoriasis,13 candida infections 
were more frequent among patients receiving 
secukinumab than among those receiving pla-
cebo, since interleukin-17 plays a role in host 
defense against bacterial and fungal infections, 
particularly at mucosal sites.35
Figure 1. Responses to Secukinumab at 24 Weeks and 52 Weeks.
Shown is the proportion of 606 patients who had an improvement of at 
least 20% in the American College of Rheumatology response criteria 
(ACR20 response), among those receiving 150 mg of secukinumab, 75 mg 
of secukinumab, or placebo. Data are shown for patients in the placebo-
controlled portion of the efficacy study, which was conducted from base-
line to week 24, and for patients who were randomly assigned to receive 
secukinumab at baseline through week 52. Missing data were imputed as 
no response to treatment through week 52. P values at week 24 were ad-
justed for multiplicity of testing. In the primary analysis through week 24, 
patients who had less than 20% improvement in the number of tender and 
swollen joints at week 16 were imputed to have had no response at weeks 
20 and 24. There was no imputation on the basis of the response at week 
16 for analyses performed at week 28 and for subsequent analyses. Asterisks 
indicate P<0.001 for the comparison with placebo.
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Several different statistical methods have 
been applied to trials involving patients with 
psoriatic arthritis. We used a rigorous assess-
ment of efficacy at week 24, with the imputation 
of missing data as no response, which provided 
a conservative estimate. One limitation of our 
study is that it did not include assessment of 
axial disease. In addition, the use of the same 
high intravenous loading dose in the two 
secukinumab groups made it difficult to iden-
tify any potential dose–response relationships. 
For ethical reasons and consistent with clinical 
trials of other biologic agents, the placebo-
controlled period of this trial was short. Thus, 
the long-term efficacy and safety of secukinum-
ab as compared with placebo cannot be deter-
mined.
In conclusion, the use of secukinumab showed 
efficacy in the key clinical domains of psoriatic 
arthritis. Adverse events that were associated 
with secukinumab included infections and car-
diovascular events. Longer and larger studies will 
be required to assess uncommon serious adverse 
effects and adverse effects associated with long-
term use of secukinumab. These results suggest 
an important role for interleukin-17A in the 
pathogenesis of psoriatic arthritis and validate 
inhibition of this cytokine as a therapeutic ap-
proach in this disease.
Supported by Novartis Pharma.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank the patients who participated in study; John Gal-
lagher, a medical consultant for Novartis Pharma; and Chris 
Strutynskyj-Stannard and Joanne Swainston, medical writers 
who are employed by Seren Communications, an Ashfield com-
pany, part of UDG Healthcare.
References
1. Boehncke WH, Menter A. Burden of 
disease: psoriasis and psoriatic arthritis. 
Am J Clin Dermatol 2013; 14: 377-88.
2. Gladman DD, Antoni C, Mease P, 
Clegg DO, Nash P. Psoriatic arthritis: epi-
demiology, clinical features, course, and 
outcome. Ann Rheum Dis 2005; 64: Suppl 2: 
ii14-ii17.
3. Mease P. Psoriatic arthritis and spon-
dyloarthritis assessment and manage-
ment update. Curr Opin Rheumatol 2013; 
25: 287-96.
4. Mease PJ, Armstrong AW. Managing 
patients with psoriatic disease: the diag-
nosis and pharmacologic treatment of 
psoriatic arthritis in patients with psoria-
sis. Drugs 2014; 74: 423-41.
5. Gossec L, Smolen JS, Gaujoux-Viala C, 
et al. European League Against Rheuma-
tism recommendations for the manage-
ment of psoriatic arthritis with pharma-
cological therapies. Ann Rheum Dis 2012; 
71: 4-12.
6. Menter A, Korman NJ, Elmets CA, et 
al. Guidelines of care for the management 
of psoriasis and psoriatic arthritis: sec-
tion 6 — guidelines of care for the treat-
ment of psoriasis and psoriatic arthritis: 
case-based presentations and evidence-
based conclusions. J Am Acad Dermatol 
2011; 65: 137-74.
7. Jandus C, Bioley G, Rivals JP, Dudler J, 
Speiser D, Romero P. Increased numbers 
of circulating polyfunctional Th17 mem-
ory cells in patients with seronegative 
spondylarthritides. Arthritis Rheum 2008; 
58: 2307-17.
8. Kagami S, Rizzo HL, Lee JJ, Koguchi 
Y, Blauvelt A. Circulating Th17, Th22, and 
Th1 cells are increased in psoriasis. J In-
vest Dermatol 2010; 130: 1373-83.
9. Lin AM, Rubin CJ, Khandpur R, et al. 
Mast cells and neutrophils release IL-17 
through extracellular trap formation in 
psoriasis. J Immunol 2011; 187: 490-500.
10. Noordenbos T, Yeremenko N, Gofita I, 
et al. Interleukin-17-positive mast cells 
contribute to synovial inf lammation in 
spondylarthritis. Arthritis Rheum 2012; 
64: 99-109.
11. Menon B, Gullick NJ, Walter GJ, et al. 
Interleukin-17+CD8+ T cells are enriched 
in the joints of patients with psoriatic ar-
thritis and correlate with disease activity 
and joint damage progression. Arthritis 
Rheumatol 2014; 66: 1272-81.
12. Mease PJ, Genovese MC, Greenwald 
MW, et al. Brodalumab, an anti-IL17RA 
monoclonal antibody, in psoriatic arthri-
tis. N Engl J Med 2014; 370: 2295-306.
13. Langley RG,Elewski BE, Lebwohl M, 
et al. Secukinumab in plaque psoriasis — 
results of two phase 3 trials. N Engl J Med 
2014; 371: 326-38.
14. Baeten D, Baraliakos X, Braun J, et al. 
Anti-interleukin-17A monoclonal antibody 
secukinumab in treatment of ankylosing 
spondylitis: a randomised, double-blind, 
placebo-controlled trial. Lancet 2013; 382: 
1705-13.
15. Taylor W, Gladman D, Helliwell P, 
Marchesoni A, Mease P, Mielants H. Clas-
sification criteria for psoriatic arthritis: 
development of new criteria from a large 
international study. Arthritis Rheum 2006; 
54: 2665-73.
16. Felson DT, Anderson JJ, Boers M, et al. 
American College of Rheumatology: pre-
liminary definition of improvement in 
rheumatoid arthritis. Arthritis Rheum 
1995; 38: 727-35.
17. Weisman S, Pollack CR, Gottschalk 
RW. Psoriasis disease severity measures: 
comparing efficacy of treatments for se-
vere psoriasis. J Dermatolog Treat 2003; 
14: 158-65.
18. Wells G, Becker JC, Teng J, et al. Vali-
dation of the 28-joint Disease Activity 
Score (DAS28) and European League 
Against Rheumatism response criteria 
based on C-reactive protein against dis-
ease progression in patients with rheu-
matoid arthritis, and comparison with 
the DAS28 based on erythrocyte sedimen-
tation rate. Ann Rheum Dis 2009; 68: 954-
60.
19. Ware JE Jr, Sherbourne CD. The MOS 
36-Item Short-Form Health Survey (SF-36). 
I. Conceptual framework and item selec-
tion. Med Care 1992; 30: 473-83.
20. Fries JF, Spitz P, Kraines RG, Holman 
HR. Measurement of patient outcome in 
arthritis. Arthritis Rheum 1980; 23: 137-45.
21. van der Heijde D, Landewé R, Klaresk-
og L, et al. Presentation and analysis of 
data on radiographic outcome in clinical 
trials: experience from the TEMPO study. 
Arthritis Rheum 2005; 52: 49-60.
22. Department of Health and Human 
Services. Common terminology criteria 
for adverse events (CTCAE), version 4.03. 
June 14, 2010 (http://evs .nci .nih .gov/ 
ftp1/ CTCAE/ CTCAE_4 .03_2010-06-14_
QuickReference_5x7 .pdf).
23. Klein U, Liang E, Vogel B, Kolbinger F, 
Bruin G, Lloyd P. Immunogenicity of the 
anti-IL-17A antibody secukinumab in 
healthy subjects and patients. J Invest 
Dermatol 2013; 133: Suppl 1: S172. abstract.
24. Bush KA, Farmer KM, Walker JS, 
Kirkham BW. Reduction of joint inflam-
mation and bone erosion in rat adjuvant 
arthritis by treatment with interleukin-17 
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on April 2, 2017. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 373;14 nejm.org October 1, 2015 1339
Secukinumab in Patients with Psoriatic Arthritis
receptor IgG1 Fc fusion protein. Arthritis 
Rheum 2002; 46: 802-5.
25. Lubberts E, Koenders MI, Oppers-
Walgreen B, et al. Treatment with a neu-
tralizing anti-murine interleukin-17 anti-
body after the onset of collagen-induced 
arthritis reduces joint inflammation, car-
tilage destruction, and bone erosion. Ar-
thritis Rheum 2004; 50: 650-9.
26. Pöllinger B, Junt T, Metzler B, et al. 
Th17 cells, not IL-17+ γδ T cells, drive ar-
thritic bone destruction in mice and hu-
mans. J Immunol 2011; 186: 2602-12.
27. Saad AA, Ashcroft DM, Watson KD, 
Hyrich KL, Noyce PR, Symmons DP. Per-
sistence with anti-tumour necrosis factor 
therapies in patients with psoriatic arthri-
tis: observational study from the British 
Society of Rheumatology Biologics Regis-
ter. Arthritis Res Ther 2009; 11: R52.
28. Glintborg B, Ostergaard M, Krogh NS, 
et al. Clinical response, drug survival, and 
predictors thereof among 548 patients with 
psoriatic arthritis who switched tumor ne-
crosis factor α inhibitor therapy: results 
from the Danish Nationwide DANBIO Reg-
istry. Arthritis Rheum 2013; 65: 1213-23.
29. Kavanaugh A, Krueger GG, Beutler A, 
et al. Infliximab maintains a high degree 
of clinical response in patients with active 
psoriatic arthritis through 1 year of treat-
ment: results from the IMPACT 2 trial. 
Ann Rheum Dis 2007; 66: 498-505.
30. Fagerli KM, Lie E, van der Heijde D, 
et al. Switching between TNF inhibitors 
in psoriatic arthritis: data from the 
 NOR-DMARD study. Ann Rheum Dis 2013; 
72: 1840-4.
31. McInnes IB, Sieper J, Braun J, et al. 
Efficacy and safety of secukinumab, a fully 
human anti-interleukin-17A monoclonal 
antibody, in patients with moderate-to-
severe psoriatic arthritis: a 24-week, ran-
domised, double-blind, placebo-controlled, 
phase II proof-of-concept trial. Ann Rheum 
Dis 2014; 73: 349-56.
32. Han C, Robinson DW Jr, Hackett MV, 
Paramore LC, Fraeman KH, Bala MV. Car-
diovascular disease and risk factors in 
patients with rheumatoid arthritis, psori-
atic arthritis, and ankylosing spondylitis. 
J Rheumatol 2006; 33: 2167-72.
33. Gladman DD, Ang M, Su L, Tom BD, 
Schentag CT, Farewell VT. Cardiovascular 
morbidity in psoriatic arthritis. Ann 
Rheum Dis 2009; 68: 1131-5.
34. Husted JA, Thavaneswaran A, Chan-
dran V, et al. Cardiovascular and other 
comorbidities in patients with psoriatic 
arthritis: a comparison with patients with 
psoriasis. Arthritis Care Res (Hoboken) 
2011; 63: 1729-35.
35. Miossec P, Korn T, Kuchroo VK. Inter-
leukin-17 and type 17 helper T cells. 
N Engl J Med 2009; 361: 888-98.
Copyright © 2015 Massachusetts Medical Society.
 
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on April 2, 2017. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
